Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase

News   Sep 09, 2013

 
Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase
 
 
 
 

RELATED ARTICLES

A Rogue Gene is Causing Seizures in Babies. Here’s How MSU Wants to Stop it

News

The researchers are closer to understanding the source of the seizures, a gene known as GNAO1 and the transformations it can take on, and potentially stopping its devastating effects by uncovering key differences in the way it functions.

READ MORE

Ingestible Drug-Delivery Materials May Improve Patient Treatment Compliance

News

Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.

READ MORE

LifeArc Becomes Technology Transfer Partner to London School of Hygiene & Tropical Medicine

News

LifeArc, the medical research charity, has partnered with London School of Hygiene & Tropical Medicine to provide a range of services in technology transfers.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE